Studies have shown that the neutrophil lymphocyte ratio (NLR) and tumor growth factor-β (TGF-β) affect the survival of HCC patients receiving anti-PD-1 immunotherapy [23, 24]. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.